Christopher T. Ritchlin, MD, MPH

Christopher T. Ritchlin, MD, MPH, is a professor of rheumatology at University of Rochester Medicine in Rochester, NY.

Dr Ritchlin’s basic science research focuses on understanding the mechanisms underlying pathologic bone resorption and new bone formation in psoriatic arthritis (PsA) and rheumatoid arthritis. His team also developed a new murine translational model of psoriasis and PsA, demonstrating that the decline in secondary bile acids is a key event in the transition to PsA.

He is the principal investigator for several clinical trials evaluating the efficacy of anti-TNF agents and other biologic molecules in the treatment of PsA, rheumatoid arthritis, and ankylosing spondylitis. Dr Ritchlin directs the National Institute of Arthritis and Musculoskeletal and Skin Diseases Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases Psoriatic Disease Team, which is focused on understanding key pathophysiological events underlying psoriasis and PsA using advanced technologies such as single-cell RNA sequencing and spatial transcriptomics.

Dr Ritchlin is the author or coauthor of more than 300 peer-reviewed articles.